British drugmaker AstraZeneca Plc may have supplied an insufficient view of efficacy data on its COVID-19 vaccine from a big scale U.S. trial, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday, in a fresh obstacle to the shot.AstraZeneca said a day previously that its COVID-19 vaccine developed with Oxford University was 79% reliable in preventing symptomatic illness in a big trial in the United States, Chile and Peru.”The DSMB revealed concern that AstraZeneca may have consisted of out-of-date details from that trial, which may have provided an insufficient view of the effectiveness data,” the U.S. company said, referring to the independent Data Safety Monitoring Board (DSMB).”We urge the business to deal with the DSMB to examine the efficacy information and ensure the most accurate, updated effectiveness data be revealed as quickly as possible.”The request cast doubts over the businesss plan to look for U.S. emergency situation usage authorization for the vaccine in the coming weeks.Authorization and standards for usage of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough evaluation of the data by independent advisory committees, said the NIAID, part of the National Institutes of Health.AstraZeneca did not instantly react to a Reuters request for remark. cnxps.cmd.push(function () ); if(window.location.pathname.indexOf(“656089”)!= -1) Hailed as a turning point in the fight against the COVID-19 pandemic when it emerged as a vaccine contender in 2015, the AstraZeneca shot has actually been dogged by doubts over its efficacy, dosing program and possible negative effects.
- Canadas largest province says its in the third wave — and officials worry the vaccine rollout may not happen fast enough – CNN
- The secret to a successful wine pairing? Fats have an affinity for tannins – Ars Technica